The Thesis
RSI Snap-Back is a mean-reversion play on the Magnificent Seven — AAPL, MSFT, NVDA, GOOGL, AMZN, META, and TSLA. The premise is straightforward: large-cap tech names tend to overshoot on short-term momentum and then revert. The strategy buys the most oversold names when their RSI drops below 35 and trims positions once RSI pushes above 70, rotating to keep a disciplined four-name book. That hard slot cap is the strategy's risk governor — it limits how much concurrent drawdown exposure the book can accumulate at any one time.
This is a well-worn academic idea applied to a narrow, liquid universe. On paper, that's a sensible pairing: mean-reversion signals are noisy, so anchoring them to seven of the most heavily traded equities on the planet reduces the risk of getting stuck in a name that simply keeps falling.
Backtest Performance
Over a 451-day window the strategy returned 20.95%, lifting a $10,000 book to $12,095 — a CAGR of 11.21%. The win rate is a healthy 66.67% across 37 trades, and trading costs were negligible ($37 in fees, no FX drag).
The less flattering numbers deserve equal billing. The Sharpe ratio of 0.61 is modest, telling us the returns came with meaningful volatility rather than smooth compounding. The maximum drawdown of 23.73% is steep — larger than a full year's worth of gains — and would test the patience of any live allocator. Turnover of 773% confirms this is an active, rotation-heavy approach; the four-slot discipline keeps the book tight, but it churns constantly to do so.
Recent Activity
Here the live tape tells a quieter story than the backtest. The last six scheduled runs — from 28 August through 3 September — each closed with 0 trades executed and 0 rejected, the book sitting entirely in cash at $10,000. No RSI reading in the Mag-7 has tripped the sub-35 entry threshold in over a week. That isn't a malfunction; it's the strategy correctly waiting for its setup. But it does mean the live account has yet to put capital to work, so none of the backtest's edge has been demonstrated in production.
Strengths and Risks
Strengths: a coherent, testable thesis; a two-thirds win rate; trivial trading costs; and a built-in position cap that enforces discipline rather than relying on discretion.
Risks: the drawdown is the headline concern — a near-24% peak-to-trough would be hard to hold through. The Sharpe suggests the returns are more about occasional big wins than consistent edge. Critically, the validation field is empty: there is no out-of-sample or walk-forward check on record, so we cannot rule out overfitting to the backtest window. And a strategy that trades this rarely in live conditions will take a long time to build a statistically meaningful track record.
Verdict
RSI Snap-Back is a credible mean-reversion candidate with a clean rationale and encouraging backtest headline numbers — but the deep drawdown, modest risk-adjusted return, and missing validation mean it should stay firmly in the show-me column until live trades accumulate.